Clinical Trial Update: Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 3]

View source ↗

Summary

This is a Phase 3 trial evaluating tafasitamab plus lenalidomide with gemcitabine and oxaliplatin versus rituximab with gemcitabine and oxaliplatin in relapsed/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Lenalidomide (lenalidomide)
• OXALIPLATIN (Oxaliplatin)
• Rituximab (rituximab)
• tafasitamab (tafasitamab)

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: DLBCL | Phase 3 | Status: RECRUITING